Iron-Chelating therapy for transfusional iron overload

New England Journal of Medicine

Volumn 364, Issue 15, 2011, Pages 1475-1477

  Solomon, Lawrence R ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FERRITIN; IRON; IRON CHELATING AGENT; HLA A3 ANTIGEN; HLA B7 ANTIGEN;

APLASTIC ANEMIA; AUTOPSY; BLOOD TRANSFUSION; HUMAN; IRON CHELATION; IRON OVERLOAD; LETTER; LIVER CIRRHOSIS; LIVER FIBROSIS; MORBIDITY; MYELODYSPLASTIC SYNDROME; PREDICTION; PRIORITY JOURNAL; SICKLE CELL ANEMIA; SURVIVAL RATE; BETA THALASSEMIA; BLOOD; ERYTHROCYTE TRANSFUSION; NOTE; GENETICS; HEMOCHROMATOSIS; HISTOCOMPATIBILITY TEST; ALLELE; DISEASE ASSOCIATION; HEMODIALYSIS; HLA TYPING; INDIVIDUALIZATION; PATIENT CARE;

ANEMIA, SICKLE CELL; BETA-THALASSEMIA; ERYTHROCYTE TRANSFUSION; FERRITINS; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; HEMOCHROMATOSIS; HISTOCOMPATIBILITY TESTING;

EID: 79954550494     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1101838     Document Type: Letter

References (5)

1. Brittenham GM. Iron-chelating therapy for transfusional iron overload. N Engl J Med 2011;364:146-56.
2. Porter JB. Pathophysiology of transfusional iron overload: contrasting patterns in thalassemia major and sickle cell disease. Hemoglobin 2009;33:Suppl 1:S37-S45.
3. Fung EB, Harmatz PR, Milet M, et al. Fracture prevalence and relationship to endocrinopathy in iron overloaded patients with sickle cell disease and thalassemia. Bone 2008;43:162-8.
4. Koren A, Fink D, Admoni O, Tennenbaum-Rakover, Levin C. Non-transferrin-bound labile plasma iron and iron overload in sickle cell disease: a comparative study between sickle cell disease and beta-thalassemic patients. Eur J Haematol 2010;84:72-8.
5. Iron loading anemias. In: Bothwell TH, Charlton RW, Cook JD, Finch CA. Iron metabolism in man. Oxford, England: Blackwell Scientific, 1979:176-7.